---
slug: pt-141
title: PT-141: Brain-Level Arousal
canonical: https://miscsubjects.com/a/pt-141
---

## PT-141 Definition and Mechanism

PT-141 (bremelanotide) is a synthetic melanocortin receptor agonist that activates central nervous system pathways for sexual arousal signaling. [human|mechanistic]

## Human Clinical Data

In two identical phase 3 randomized double-blind placebo-controlled trials (RECONNECT), subcutaneous bremelanotide 1.75 mg as needed produced statistically significant increases in Female Sexual Function Index-desire domain scores and reductions in Female Sexual Distress Scale scores versus placebo in premenopausal women with hypoactive sexual desire disorder. [human]

Bremelanotide received FDA approval in 2019 as Vyleesi for acquired generalized hypoactive sexual desire disorder in premenopausal women. [human]

## Preclinical Context

Animal studies indicate melanocortin receptor activation in hypothalamic regions linked to sexual behavior. [preclinical]

## Evidence Summary

No human data on long-term use beyond 52-week open-label extensions in the provided trials. User reports exist outside regulated studies but are not graded here.
